Fosamax Osteonecrosis of the Jaw Attorney: Statute of Limitations for Fosamax in Illinois

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Awareness to Targeted Exposure Concerns

For decades, general health and science communication has served as a foundational pillar for public understanding, offering broad guidance on wellness, disease prevention, and the safe use of medical interventions. This legacy context established a baseline of trust and awareness, enabling individuals to engage with complex health information and make informed decisions. Within this framework, the safe administration of prescription medications has always been a central concern, emphasizing the importance of monitoring for adverse effects and understanding patient-specific risk factors. As the scope of health information has evolved, a natural progression has emerged from general awareness to more targeted, exposure-focused inquiries. One such area of heightened scrutiny involves the long-term use of bisphosphonate therapies, particularly in populations with chronic bone conditions. The transition from a general health lens to a specific occupational or therapeutic exposure concern requires careful attention to the circumstances under which patients receive these treatments. In the context of mass production and widespread prescription, the focus shifts to the cumulative exposure risk and the legal frameworks that govern accountability. This pivot acknowledges that while general health guidance remains valuable, the real-world implications of sustained medication use demand a more granular examination of individual exposure histories and the timelines that define legal recourse.

Understanding Fosamax and Its Association with Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication indicated for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw that can occur spontaneously or following dental procedures. Clinical presentation and diagnosis of ONJ typically involve symptoms such as pain, swelling, infection, and delayed healing after tooth extraction or other invasive dental work. The condition is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanisms, Incidence, and Warning Adequacy

The mechanistic pathways linking Fosamax to ONJ involve the drug's pharmacology as a bisphosphonate, which inhibits bone resorption by osteoclasts. This suppression of bone turnover can impair the jaw's ability to repair microdamage and respond to infection or trauma, particularly after dental procedures. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The incidence of ONJ is considered rare; one study noted that the incidence of atypical femoral fracture or osteonecrosis of the jaw was uncommon and rare, respectively (https://pubmed.ncbi.nlm.nih.gov/42046648/). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw, detailing risk factors and recommendations. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also notes that the optimal duration of use has not been determined, and for patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Fragility fracture was not associated with interruption of bisphosphonate prescription for up to two years, after either three or five years of prescription (https://pubmed.ncbi.nlm.nih.gov/42046648/).

Statute of Limitations for Fosamax Claims in Illinois

For affected patients in Illinois considering legal action, attorney-related considerations include the statute of limitations for filing a claim. In Illinois, the statute of limitations for personal injury claims, including those related to pharmaceutical injuries, is generally two years from the date the injury was discovered or should have been discovered. The timeline between exposure to Fosamax and documented harm is critical, as ONJ can develop after months or years of use. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients who have experienced ONJ after taking Fosamax should consult with an attorney to determine if their claim falls within the applicable statute of limitations. The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1), so long-term users may be at higher risk. In summary, Fosamax is associated with a rare but serious risk of osteonecrosis of the jaw, with onset ranging from days to months after starting the drug. The prescribing information includes warnings and risk factors, and discontinuation may reduce risk. Patients in Illinois should be aware of the statute of limitations for filing claims and seek legal advice promptly if they have developed ONJ after Fosamax use.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in Illinois?

In Illinois, the statute of limitations for personal injury claims, including those related to pharmaceutical injuries, is generally two years from the date the injury was discovered or should have been discovered. Patients who have developed ONJ after taking Fosamax should consult with an attorney promptly to determine if their claim falls within this timeframe.

How long after starting Fosamax can osteonecrosis of the jaw develop?

The time to onset of ONJ symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk may increase with longer duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.